Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Endocrine Disorders Testing Market $15.8 Billion by 2027

The global market for endocrine disorders testing expected to attain $15.8 billion by 2027, growing at CAGR 6.9% over the forecast period, driven by increasing incidence of endocrine disorders such as diabetes, thyroid disorders, and infertility, rising healthcare awareness among the population, growing elderly population, and technological advancements.

  • The use of technological platforms for the analysis of several endocrine hormones is essential to ensure precise and accurate test results.
    • Major factors driving the growth of several diagnostic technologies are increased laboratory automation, constant technological upgrades, enhanced capabilities, and introduction of innovative technologies for analysis.
Global Endocrine Disorders Testing Market

The endocrine system uses a variety of hormones to regulate many different functions in the body such as growth, metabolism, and reproduction. Endocrine disorders can result in hormone overproduction (hyperfunction) or underproduction (hypofunction) or dysfunction because of the feedback mechanisms involved in the endocrine system.

  • Every gland of the endocrine system such as pineal, pituitary, and thyroid and secretory organs such as hypothalamus and pancreas, releases specific hormones into bloodstream to regulate the body functioning.
    • Some hormones (cortisol, follicle-stimulating hormone, luteinizing hormone) have a daily or monthly pattern of release.
      • Other hormones are generally present in very small quantities in the blood and are released in specific situations, such as the release of epinephrine (adrenaline) from the adrenal glands in response to stress.
    • The endocrine disorder tests help in detecting the deviations in the secretion of the hormones to understand the disorders like infertility, menopause, thyroid dysfunction.
  • Although, there are many different types of endocrine disorders, diabetes is the most common endocrine disorder diagnosed in the U.S.
    • There are many diagnostic tests including radiologic evaluations and biochemical procedures for measuring circulating hormones to determine problems in the endocrine system. Maximum number of diagnostic tests are performed in commercial laboratories followed by hospital settings.
Endocrine Disorders Testing Market

The global market for endocrine disorders testing report provides market size ($million 2017 to 2027), market share, growth trends and forecast (CAGR%, 2021 to 2027).

Browse endocrine disorders testing market by test type [cortisol test, dehydroepiandrosterone sulfate test, estradiol test, follicle stimulating hormone test, human chorionic gonadotropin test, insulin test, luteinizing hormone test, progesterone test, prolactin test, testosterone test, thyroid stimulating hormone test, other tests (gastrin, thymosin, secretin)], diagnostic technology (tandem mass spectrometry, immunoassay technologies, monoclonal and polyclonal antibody technologies, sensor technologies, clinical chemistry technologies, other technologies), end user (hospitals, commercial laboratories, ambulatory care centers, home-based tests, physician offices, others), and geography.

  • Based on the test types, the thyroid stimulating hormone (TSH) tests segment accounted for the largest share of the total market, owing to globally increasing number of thyroid dysfunction cases.
    • The TSH tests are performed to determine proper functioning of thyroid glands and are prescribed to confirm suspicious symptoms of hyperthyroidism, hypothyroidism, or an enlarged thyroid.
    • On the other hand, the insulin tests segment predicted to witness fastest growth rate during the coming years, attributed to increasing diabetic population across the globe, and high demand for detection and monitoring insulin levels in body fluids and management of diabetes.
      • Insulin tests are performed to evaluate the cause of hyperglycemia (high blood glucose level), hypoglycemia (low blood glucose level), or other conditions related to abnormal insulin production.
  • In terms of diagnostic technologies, the immunoassay technologies segment dominated the the global market, owing to rigorous use of immunoassays, specially radioimmunoassay (RIA), and enzyme linked assays (EIA) for determination of the levels of the hormone from the biological sample.
    • Similarly, advances in immunoassays led to information about early diagnosis and progression of the disease, leading to better medications minimizing the severity of the illnesses.
    • However, the tandem mass spectrometry (MS/MS) segment anticipated to record the highest double-digit CAGR in the next few years, owing to its high specificity and accuracy in determination with significant improvements in assays performance in areas such as endocrinology, toxicology, and biochemical genetics over immunoassay technologies.
      • Secondly, the growing intrinsic faults of immunoassays, specifically for the measurement of small molecules, has resulted in significant amplification and implementation of mass spectrometry in clinical applications.
  • Amon the end users, the commercial laboratories segment led the global endocrine disease testing market, driven by the use of specialized diagnostics instruments, presence of dedicated and skilled laboratory personnel, swift turn around for diagnostics services and advances in telehealth services.
    • The home-based tests segment expected to register fastest growth rate in the near future, owing to availability of low-cost and less time consuming test kits, increasing healthcare awareness among the patients, and easy access and operation resulting in an instant test result using a wide range of test kits available in the market.

The global market for endocrine disorders testing research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

The global market for endocrine disorders testing report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.

Major competitors operating in the global market for endocrine disorders testing and profiled in this report include Abbott Laboratories, Inc., AB Sciex Pte. Ltd., Agilent Technologies, Inc., Biomedical Diagnostics, bioMerieux SA, Bio-Rad Laboratories, Inc., DiaSorin S.p.A., F. Hoffmann-La Roche AG (Roche Holding AG), Laboratory Corporation of America Holdings (LabCorp), Ortho-Clinical Diagnostics, Quest Diagnostics, Healthineers AG, Sysmex Corporation, and Thermo Fisher Scientific, Inc.

  • Test Type
    • Cortisol Test
    • Dehydroepiandrosterone Sulfate (DHEAS) Test
    • Estradiol (E2) Test
    • Follicle Stimulating Hormone (FSH) Test
    • Human Chorionic Gonadotropin (hCG) Test
    • Insulin Test
    • Luteinizing Hormone (LH) Test
    • Progesterone (P4) Test
    • Prolactin Test
    • Testosterone Test
    • Thyroid Stimulating Hormone (TSH) Test
    • Other Tests (Gastrin, Thymosin, Secretin, etc.)
  • Technology
    • Tandem Mass Spectrometry
    • Immunoassay Technologies
    • Monoclonal and Polyclonal Antibody Technologies
    • Sensor Technologies
    • Clinical Chemistry Technologies
    • Other Technologies
  • End Users
    • Hospitals
    • Commercial Laboratories
    • Ambulatory Care Centers
    • Home-based Tests
    • Physician Offices
    • Others
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  • Company Profiles
    • Abbott Laboratories, Inc.
    • AB Sciex Pte. Ltd.
    • Agilent Technologies, Inc.
    • Biomedical Diagnostics
    • bioMerieux SA
    • Bio-Rad Laboratories, Inc.
    • DiaSorin S.p.A.
    • F. Hoffmann-La Roche AG (Roche Holding AG)
    • Laboratory Corporation of America Holdings (LabCorp)
    • Ortho-Clinical Diagnostics
    • Quest Diagnostics
    • Siemens Healthineers AG
    • Sysmex Corporation
    • Thermo Fisher Scientific, Inc.

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/endocrine-laboratory-testing-market/

Related publications:



    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]

    Subject*

    Message*

    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 463-5840
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: [email protected]